Yes, clascoterone cream 1%—marketed under the brand name Winlevi®—is indeed the first FDA-approved topical medication that blocks androgen receptors directly at the skin level. The FDA approved it on August 26, 2020, for the treatment of acne vulgaris in patients 12 years and older, making it the first acne drug with this specific mechanism of action approved in nearly 40 years. What makes this development significant is that it targets acne at a fundamental hormonal level without the systemic effects of oral medications like spironolactone or isotretinoin, offering a new pathway for people whose acne is driven or worsened by androgens. This approval represents a genuine shift in how dermatologists can address hormone-influenced acne topically.
Instead of relying on antibiotics, retinoids, or benzoyl peroxide alone, clascoterone works by competing with dihydrotestosterone (DHT)—the hormone that fuels acne in androgen-sensitive skin—for receptor binding sites in the pilosebaceous unit (the hair follicle and sebaceous gland). This prevents DHT from triggering excess sebum production and inflammatory cytokine release, two primary drivers of acne formation. The medication became commercially available in the United States in November 2021. This article explores how clascoterone works, what the clinical evidence shows about its effectiveness, who benefits most from this treatment, potential side effects, and how it compares to existing acne therapies.
Table of Contents
- What Does It Mean to Block Androgen Receptors at the Skin Level?
- How Clascoterone Inhibits the Acne Cascade at the Cellular Level
- Clinical Trial Evidence and Real-World Efficacy
- Who Benefits Most From Clascoterone, and Practical Considerations for Use
- Safety Profile and Potential Adverse Effects
- How Clascoterone Compares to Other Hormonal Acne Treatments
- The Significance of This Innovation and Future Developments
- Conclusion
What Does It Mean to Block Androgen Receptors at the Skin Level?
acne has a hormonal component that many standard topical treatments cannot address. Androgens—male hormones present in all bodies but at varying levels—bind to receptors on skin cells and sebaceous glands, triggering increased oil production and inflammatory responses. Clascoterone functions as a competitive antagonist to androgen receptors, meaning it physically blocks DHT from attaching to these receptor sites within the skin itself, without affecting systemic hormone levels throughout the body. The significance of this skin-level targeting cannot be overstated.
Oral medications like spironolactone, which is sometimes prescribed off-label for hormonal acne, work by reducing circulating androgens throughout the entire body—a systemic effect that carries risks including electrolyte imbalances, blood pressure changes, and potential impacts on reproductive health. Clascoterone, by contrast, localizes its action to the skin and pilosebaceous units. A patient using clascoterone does not experience reduced facial hair growth elsewhere on the body, hormonal shifts, or the need for potassium monitoring and regular blood tests that accompany systemic androgen blockers. This makes it particularly valuable for people who have androgen-driven acne but cannot tolerate or prefer to avoid the systemic effects of oral hormone-modulating medications.
How Clascoterone Inhibits the Acne Cascade at the Cellular Level
The mechanism by which clascoterone prevents acne is rooted in blocking DHT’s downstream effects within skin cells. When DHT binds to androgen receptors in sebaceous glands, it activates a cascade: increased lipid synthesis (making skin oilier), upregulation of inflammatory cytokines, and enhanced colonization by Cutibacterium acnes (formerly Propionibacterium acnes), the bacterium central to acne inflammation. By occupying the androgen receptor binding site first, clascoterone prevents DHT from triggering this entire chain of events. However, it’s important to understand that clascoterone does not reduce circulating DHT levels or affect androgen production. Someone using this medication will still produce normal amounts of androgens; the drug simply prevents those androgens from exerting their acne-promoting effects in the skin.
This distinction matters for patients concerned about hormonal changes. If someone’s acne is driven by systemic hormonal imbalances—such as polycystic ovary syndrome (PCOS) or other endocrine conditions—clascoterone may help manage the skin manifestation without treating the underlying condition. In those cases, a dermatologist might recommend combination therapy or referral to an endocrinologist alongside topical androgen receptor blockade. The local mechanism also means that clascoterone works best on acne driven by androgen sensitivity rather than acne caused solely by bacteria, retention of dead skin cells, or irritation. Patients with primarily inflammatory or cystic acne without a clear androgen component may see less benefit compared to those with hormonal or adult-onset acne, particularly in the lower face and jawline areas where androgen-sensitive acne typically clusters.
Clinical Trial Evidence and Real-World Efficacy
The FDA approval of clascoterone was based on two Phase 3 double-blind, vehicle-controlled trials involving 1,440 patients total. In Trial 1, patients using clascoterone achieved an 18.4% success rate (defined as achieving clear or almost clear skin and at least a 75% reduction in lesion count) compared to 9.0% with vehicle control after 12 weeks. Trial 2 showed even stronger results: 20.3% success with clascoterone versus 6.5% with vehicle. Both trials demonstrated statistically significant improvements.
These efficacy numbers are respectable but warrant honest interpretation. A 20% success rate for “clear or nearly clear” skin means that 80% of trial participants did not achieve that level of clearing, though many experienced meaningful improvement. Clascoterone performed considerably better than placebo but generally shows more modest results than stronger options like topical retinoids or oral isotretinoin. The drug appears most effective when used as part of a combination regimen—for instance, pairing it with a retinoid or benzoyl peroxide—rather than as monotherapy. Some dermatologists recommend it particularly for patients whose acne flares predictably with their menstrual cycle or who have confirmed androgen sensitivity (elevated testosterone, PCOS, or acne responding previously to spironolactone) and want a topical-only option.
Who Benefits Most From Clascoterone, and Practical Considerations for Use
Clascoterone is indicated for patients ages 12 and older with acne vulgaris, but it is not equally effective for all acne presentations. The best candidates are those with adult-onset or hormonal acne—characterized by persistent breakouts in the lower face, jawline, and neck areas, often worsening around menses or during hormonal fluctuations. Patients with a history of improvement on spironolactone are strong candidates, as are those unable to take oral medications due to pregnancy, breastfeeding, kidney disease, or other contraindications. For practical use, clascoterone is applied topically once or twice daily, similar to other prescription acne creams. It comes as a 1% cream formulation and is currently available by prescription only. The medication may be combined with other acne treatments—a fact often overlooked by patients who assume they must choose between clascoterone and their retinoid or benzoyl peroxide.
In fact, dermatologists frequently prescribe clascoterone alongside retinoids or benzoyl peroxide for synergistic benefit. One important consideration: clascoterone has no significant interaction with contraceptive medications, making it a particularly practical option for patients on birth control pills who want additional acne management without concerns about drug interactions. Insurance coverage varies considerably. Some plans cover clascoterone as a first-line topical acne treatment, while others classify it as a specialty medication requiring prior authorization or limiting it to cases where standard treatments have failed. Cost without insurance can exceed $300 per month, which influences access. Patients should check with their insurance or use manufacturer coupons (if available) before filling the prescription.
Safety Profile and Potential Adverse Effects
Clascoterone demonstrated a favorable safety profile in clinical trials, with most adverse events being mild and resolving without discontinuation of the medication. The most commonly reported side effects were erythema (redness) and pruritus (itching), each occurring in approximately 7–12% of patients in the trials. Scaling or dryness was reported at similar rates. These side effects are generally milder and less frequent than those associated with tretinoin or isotretinoin, which can cause significant irritation and peeling. Because clascoterone does not absorb systemically to any meaningful degree, there is no risk of the systemic adverse effects associated with oral androgen blockers. Blood pressure changes, electrolyte disturbances, and hormonal side effects are not concerns.
However, as with any topical medication, local sensitivity is possible. People with known sensitivity to any component of the formulation should not use it. Additionally, clascoterone has not been extensively studied in pregnant individuals, so it is generally recommended to avoid its use during pregnancy unless the benefit clearly outweighs potential risks—a conversation best had with both a dermatologist and obstetrician. There is minimal data on use during breastfeeding, and caution is advised. Irritation can be managed by starting with once-daily application and titrating to twice daily if tolerated, or by spacing applications if concurrent irritating treatments (like tretinoin) are being used. The cream formulation is generally less irritating than alcohol-based gels or solutions, which may explain its favorable tolerability profile in trials.
How Clascoterone Compares to Other Hormonal Acne Treatments
For patients seeking hormonal acne management, the landscape includes oral spironolactone, oral isotretinoin, and now topical clascoterone. Spironolactone is an oral potassium-sparing diuretic that blocks androgen receptors systemically and has decades of off-label use for female hormonal acne. It is inexpensive (often under $20 per month with insurance), has strong clinical support, but requires blood pressure monitoring and cannot be used in pregnancy. Isotretinoin (Accutane) is the most powerful acne medication but carries significant risks (severe birth defects, potential mood changes, elevated liver enzymes) and is reserved for severe, scarring acne unresponsive to other treatments.
Clascoterone occupies a middle ground: stronger than standard topical treatments and free from systemic hormonal effects, but less potent than oral alternatives. Someone unable to take spironolactone because they are pregnant, breastfeeding, or have kidney disease might find clascoterone a reasonable option. Someone whose acne is mild to moderate and androgen-driven might achieve adequate control with clascoterone plus a retinoid, avoiding oral medication entirely. Conversely, someone with severe, cystic, or widespread acne may find clascoterone insufficient and require isotretinoin. The choice depends on acne severity, medical history, pregnancy status, and individual preference regarding systemic versus topical treatment.
The Significance of This Innovation and Future Developments
The FDA approval of clascoterone in 2020 and its subsequent commercial launch represent a meaningful expansion of acne treatment options, even if it is not a revolution. For nearly 40 years, the topical acne armamentarium remained largely unchanged: retinoids, benzoyl peroxide, antibiotics, and azelaic acid. The addition of a topical androgen receptor antagonist acknowledges that hormonal acne is a distinct category requiring distinct treatment approaches and validates the scientific rationale for targeting androgen signaling at the skin level.
Going forward, the question is whether other topical androgen antagonists will be developed, or whether combination formulations pairing clascoterone with complementary agents (retinoids, benzoyl peroxide) will emerge. Additionally, there is potential for clascoterone to be studied in other androgen-driven skin conditions beyond acne—such as androgenetic alopecia or hirsutism—though such applications remain investigational. For now, clascoterone (Winlevi) remains the only topical androgen receptor inhibitor available in the United States, offering patients and dermatologists a distinctly new tool for managing androgen-sensitive acne without systemic hormonal effects.
Conclusion
Clascoterone cream 1% is indeed the first FDA-approved topical medication that blocks androgen receptors at the skin level, approved by the FDA on August 26, 2020, and commercially available since November 2021. By preventing dihydrotestosterone from binding to androgen receptors in pilosebaceous units, it addresses a fundamental driver of hormonal acne without the systemic effects of oral medications.
Clinical trial data shows meaningful but modest efficacy—approximately 18–20% of patients achieving clear or nearly clear skin—that improves when combined with other acne treatments. For the right patient—particularly those with adult-onset or menstrual-cycle-related acne, those unable to tolerate or access oral androgen blockers, and those seeking a topical-only approach—clascoterone offers a scientifically sound and well-tolerated option. If you have androgen-driven acne and are curious whether this treatment might work for you, a conversation with a dermatologist can clarify whether your acne pattern suggests androgen sensitivity and whether clascoterone, potentially combined with retinoids or benzoyl peroxide, aligns with your treatment goals and circumstances.
You Might Also Like
- She Had Clear Skin Her Whole Life Until She Moved to a Humid Climate at Age 28
- Fact Check: Is SPF 30 Enough for Acne-Prone Skin on Retinoids? Minimum SPF 30 Is Essential Because Retinoids Increase Sun Sensitivity
- Fact Check: Can Witch Hazel Replace Toner for Acne-Prone Skin? It May Reduce Oil but Can Also Irritate Sensitive Skin
